|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 874.45 INR | +1.94% |
|
-3.54% | -3.22% |
| 12-02 | NATCO Pharma Limited Announces Executive Changes | CI |
| 11-24 | NATCO Pharma Gets Seven Observations in US FDA Inspection at Chennai API Unit | MT |
| Capitalization | 154B 1.7B 1.46B 1.36B 1.27B 2.36B 2.54B 15.64B 6.15B 73.51B 6.39B 6.26B 270B | P/E ratio 2026 * |
12.2x | P/E ratio 2027 * | 22.8x |
|---|---|---|---|---|---|
| Enterprise value | 154B 1.7B 1.46B 1.36B 1.27B 2.36B 2.54B 15.64B 6.15B 73.51B 6.39B 6.26B 270B | EV / Sales 2026 * |
3.94x | EV / Sales 2027 * | 5.47x |
| Free-Float |
49.09% | Yield 2026 * |
0.85% | Yield 2027 * | 0.56% |
More valuation ratios
* Estimated data
More news
Last Transcript: NATCO Pharma Limited
More recommendations
More press releases
More news
| 1 day | +1.88% | ||
| 1 week | -3.54% | ||
| Current month | -3.22% | ||
| 1 month | -3.49% | ||
| 3 months | +4.07% | ||
| 6 months | -10.53% | ||
| Current year | -3.22% |
| 1 week | 862 |  | 960.4 |
| 1 month | 862 | | 960.4 |
| Current year | 862 | | 960.4 |
| 1 year | 726.8 | | 1,341 |
| 3 years | 502 | | 1,639 |
| 5 years | 502 | | 1,639 |
| 10 years | 390 | | 1,639 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 02/07/2000 | |
| Director of Finance/CFO | - | - | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 80 | 03/10/1981 | |
| Director/Board Member | 48 | 02/07/2000 | |
| Director/Board Member | 73 | 10/02/1993 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +4.72% | 0.01% | 51 M€ | |
| +3.29% | 0% | 51 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.94% | -3.54% | -27.88% | +56.60% | 1.7B | |
| +1.64% | +3.79% | +35.14% | +201.01% | 968B | |
| +2.61% | +2.65% | +47.63% | +20.53% | 505B | |
| -0.02% | -0.06% | +25.62% | +44.55% | 389B | |
| +0.50% | +5.22% | +29.29% | +18.53% | 367B | |
| -0.68% | +5.50% | +30.47% | +23.34% | 295B | |
| -1.21% | +1.63% | +10.02% | -2.31% | 271B | |
| -0.18% | +4.92% | +25.39% | +35.33% | 274B | |
| -0.62% | +9.33% | -38.17% | -17.02% | 263B | |
| -0.17% | +1.50% | +24.14% | +20.16% | 175B | |
| Average | +0.17% | +2.92% | +16.16% | +40.07% | 350.99B | |
| Weighted average by Cap. | +0.39% | +3.71% | +26.10% | +69.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.98B 433M 370M 344M 321M 600M 644M 3.97B 1.56B 18.65B 1.62B 1.59B 68.38B | 28.08B 312M 267M 248M 231M 432M 464M 2.86B 1.12B 13.43B 1.17B 1.14B 49.26B |
| Net income | 12.49B 139M 119M 110M 103M 192M 206M 1.27B 500M 5.98B 520M 509M 21.91B | 6.47B 71.79M 61.47M 57.17M 53.3M 99.58M 107M 659M 259M 3.1B 269M 264M 11.35B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
4,199
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/01/26 | 874.45 ₹ | +1.94% | 283,888 |
| 12/01/26 | 857.85 ₹ | -3.63% | 914,840 |
| 09/01/26 | 890.20 ₹ | -2.14% | 758,205 |
| 08/01/26 | 909.70 ₹ | -3.85% | 550,397 |
| 07/01/26 | 946.10 ₹ | +2.18% | 1,817,099 |
Delayed Quote NSE India S.E., January 13, 2026 at 05:31 am
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
857.85INR
Average target price
970.36INR
Spread / Average Target
+13.12%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NATCOPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition